Respiratory syncytial virus prophylaxis

Palivizumab Synagis Humanized Respiratory syncytial virus prophylaxis... 

Palivizumab F protein of respiratory syncytial virus Prophylaxis of serious lower respiratory tract disease Hypersensitivity... 

Prophylaxis of lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients... 

Currently, 17 mAbs have been approved in the United States (US) for therapeutic use in organ transplant, percutaneous coronary intervention, prophylaxis of respiratory syncytial virus, RA, Crohn s disease, asthma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, non-Hodgkin s lymphoma, breast cancer, and colorectal cancer. All approved mAbs are of the IgG class 13 human IgG1 one igG4, and two murine IgG2a. Thirteen are intact mAbs, three are conjugated, and one is a Fab fragment (Tables 12.2 to 12.4). 

Wenzel SE, Gibbs RL, Lehr MV Simoes EA Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med 2002 112 627-633. 

In infants with underlying pulmonary or cardiovascular disease, prophylaxis against RSV may be warranted. When administered monthly during the RSV season, both respiratory syncytial virus immune globulin (RSVIG) and palivizumab (a monoclonal antibody for RSV) may decrease the number of RSV episodes and the need for hospitalization. Among the two, palivizumab appears to be preferred, given its ease of administration, lack of administration-related adverse effects, and noninterference with select immunizations. 

The Prevent Study Group. Reduction of respiratory syncytial virus hospitalizations among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. 

Synagis (Palivizumab humanized mAb directed against an epitope on the surface of respiratory syncytial virus) Medimmune (US) and Abbott (EU) prophylaxis of lower respiratory tract disease caused by respiratory syncytial virus in pediatric patients 1998 (US), 1999 (EU)... 

Greenough A. Recent advances in the management and prophylaxis of respiratory syncytial virus... 

Twenty-five years after their advent, monoclonal antibodies (MAbs) have emerged as an important and rapidly expanding new dmg class for the treatment of severe human diseases (1-3). Ten antibodies have been approved in the United States for diverse cUnical indications cancer, transplant rejection, Crohn s disease, respiratory syncytial virus (RSV) prophylaxis, and as an anti-thrombotic (Table 1). An additional 70 or so antibody therapeutics are in clinical trials in the United States including at least 46 that have progressed to phase I/n or farther (Table 2). This chapter focuses on recent developments with antibody therapeutics from a biotechnology perspective. 

---